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Th17 cells provide protective immunity to infections by fungi and extracellular bacteria as well as cancer but are also involved
in chronic inflammation. The cells were first identified by their ability to produce interleukin 17A (IL-17A) and, subsequently,
associated with chronic inflammation and autoimmunity. Th17 cells have some gene profile similarity with stem cells and can
remain dormant in mucosal tissues for long periods. Indeed, recent studies suggest that functionally distinct subsets of pro-
and anti-inflammatory Th17 cells can interchange phenotype and functions. For development, Th17 cells require activation of the
transcription factors STAT3 and ROR𝛾t while RUNX1, c-Maf, and Aiolos are involved in changes of phenotype/functions. Attempts
to harnessTh17 cells against pathogens and cancer using vaccination strategies are being explored.The cells gain protective abilities
when induced to produce interferon 𝛾 (IFN𝛾). In addition, treatment with antibodies to IL-17 is effective in treating patients with
psoriasis, psoriatic arthritis, and refectory rheumatoid arthritis. Moreover, since ROR𝛾t is a nuclear receptor, it is likely to be a
potential future drug target for modulatingTh17 functions.This review explores pathways through whichTh17 subsets are induced,
the molecular basis of their plasticity, and potential therapeutic strategies for their modulation in diseases.
1. Introduction
Different subsets of helper T cells (Th) have been identified
based, primarily, on the pattern of cytokines they produce.
The Th1 subset is induced to differentiate in response to
intracellular pathogens and viruses to produce IFN𝛾 and
TNF𝛼 and initiate cellular immunity. The Th2 subset, in
contrast, produces interleukin 4 (IL-4), IL-5, and IL-13 and
mediates immunity to helminths and parasites as well as
initiating humoral immunity. Regulatory T cells, which were
discovered subsequently, dampen inflammatory responses
against foreign and self-antigens through cell-cell interac-
tions and produce IL-10 and TGF𝛽 [1]. The most recent
addition to effector Th subsets is Th17 cells that were iden-
tified in 2006 based on their ability to produce IL-17A [2].
Although the latest to be discovered, subsequent evolutionary
studies have established that the Th17 subset is the most
ancient one. Hence, immune cells equipped with a nascent
T cell receptor (TCR) from the primitive fish lamprey, whose
lineage diverged from that of humans 500 million years ago,
produce IL-17 but none of the cytokines associated with
the other T cell lineages [3]. In mammals, at homeostasis
commensal bacteria in the gut induce IL-1𝛽 production to
maintain a basal level of Th17 cells in the lamina propria [4].
However, in response to pathogenic extracellular bacterial
and fungal infections at mucocutaneous surfaces in the
intestine, the respiratory tract, and the skin, large numbers of
naiveTh cells differentiate toTh17 cells under the influence of
IL-1𝛽, IL-6, IL-23, and/or TGF𝛽 [5]. In addition to producing
IL-17A,Th17 cells can produce IL-17F, IL-21, IL-22, IFN𝛾, and
GM-CSF [6, 7]. IL-17A, referred to as IL-17 in this review,
has pleiotropic properties after binding IL-17 receptors on
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haematopoietic and nonhaematopoietic cells such as epithe-
lial and endothelial cells [8].The binding of IL-17 to its recep-
tors triggers intracellular signalling that induces the pro-
duction of proinflammatory cytokines such as IL-6, C-X-C
chemokines such as chemokine 8 (CXCL8), CXCL9, CXCL10,
and CXCL11, and beta-defensin-2 [9–11]. During acute infec-
tions, Th17 cells recruit neutrophils and, thereby, mediate
initial protection frompathogens [8]. Furthermore, IL-21 and
IL-22 produced byTh17 cells protect mucosal membranes by
inducing the production of antimicrobial proteins, RegIII𝛽,
and RegIII𝛾 and by stimulating B cells [6, 7]. IL-17 is, by
itself, a weak activator of other immune cells and studies have
shown that the presence of other cytokines, such as TNF𝛼 or
IL-1𝛽, is required formaximumeffects of the cytokine [12, 13].
After their activation, effector and memory Th17 cells
can remain dormant in the mucosa for extended periods
of time [14]. A number of recent studies have revealed that
Th17 cells show a great degree of functional and phenotypic
plasticity. Thus, there is evidence that Th17 cells can change
to Th1-like cells or acquire the ability to produce IL-10
which can be beneficial during certain types of infections.
For example, Candida albicans induces IFN𝛾 production by
Th17 cells while Staphylococcus aureus induces IL-10 [15].
With regard to phenotype, all Th17 cells express CCR6
and most also express CD161 [16]. Th17 cells that only
produce IL-17 express CCR4 while IFN𝛾-producing Th17
cells express CXCR3 [17]. In addition to providing protective
immunity and driving chronic inflammation, Th17 cells have
been suggested to play a dual role in tumour development.
Thus, Th17 cells have been implicated in promoting tumour
through producing angiogenic factors but, paradoxically, also
shown to counteract tumour development by producing IL-
17 and IFN𝛾 [18]. Treatment of patients with the epidermal
skin disorder psoriasis with antibodies to IL-17 or with
its soluble recombinant receptor leads to remission [19,
20]. Furthermore, patients with rheumatoid arthritis (RA),
psoriatic arthritis, and ankylosing spondylitis have been
reported to benefit from treatment with biologic inhibitors
of IL-17 [21–23]. However, treatment of patients with Crohn’s
disease with inhibitors of IL-17 worsens disease, perhaps,
highlighting some protective functions for Th17 cells in
the gastrointestinal tract [24]. Interestingly, there is some
evidence to indicate that the ability of Th17 cells to promote
pathology in autoimmune diseases is acquired when the cells
gain the ability to produce IFN𝛾. In animal models of disease,
these cells were shown to express receptors for either IL-23 or
IL-1𝛽 [25, 26].
This reviewwill explore potential strategies to harness the
use ofTh17 cells for therapeutic purposes. First, wewill review
available evidence on the signals that promote the develop-
ment ofTh17 cells and mechanisms that underpin changes to
their phenotype. These involve TCR- and cytokine-mediated
signals, transcription factors, and epigenetic modifications.
Second, studies aimed at employingTh17 cells for vaccination
against various organisms and for protection from cancers
will be reviewed. We will also discuss advantages and pitfalls
of reported experimental strategies and contemplate whether
it would be beneficial to alter the phenotype of Th17 cells in
human diseases.
2. Th17 Cell Development, Transcriptional
Regulation, and Functional Plasticity
The available evidence indicates that Th17 cell progenitors,
identified byCD161 expression, are present atmucocutaneous
sites and in peripheral and cord blood [16]. These cells are
induced to differentiate into effector Th17 cells by cytokines
that activate a highly regulated transcriptional network
involving at least five transcription factors and through epige-
netic modifications. Cytokines IL-1𝛽, IL-6, TGF𝛽, and IL-23
and the lipid mediator PGE
2
have all been variably reported
to be involved in Th17 cell differentiation [27]. An initial
medium level of T cell receptor (TCR) engagement activates
the nuclear factor kappa B (NF𝜅B) which, in turn, activates
the interferon regulatory factor 4 transcription factor (IRF4).
In contrast, high level TCR engagement preferentially pro-
motes Th1 cell differentiation. The two transcription factors
togetherwith another transcription factor called basic leucine
zipper transcription factor ATF-like (BATF), binds multiple
sites throughout the chromatin [28–30]. IL-1𝛽 increases
the expression of IRF4 [31] while IL-6 and IL-23 induce
the phosphorylation of signal transducer and activator of
transcription 3 (STAT3). This leads to the disassociation
of STAT3 from the receptor-bound Janus kinase 2 (JAK2).
Phosphorylated STAT3 then transmigrates to the nucleus and
populates many DNase sensitive chromosomal sites, made
accessible by TGF𝛽, and stabilizes some of the BATF/IRF4
interactions [28]. IL-23 also induces the expression of a
fourth transcription factor, runt-related transcription factor
1 (RUNX1) [32]. RUNX1/3 promotes Th17 differentiation by
enhancing expression of the transcription factor ROR𝛾t and
increasing its stability at the Il17 locus [33]. The transcription
factor ROR𝛾t is a signature transcription factor forTh17 cells
as it binds a number of specific DNA loci critical for the
differentiation of the cells [28].
Numerous studies have highlighted the plasticity of Th17
cells [32, 34–36]. Although key Th17-specific loci (e.g., Il17a,
Il17f, and Rorc) are known to be accessible in all Th17
cells, they have also been reported to be easily repressed.
TGF𝛽 has been shown to stabilize the open state of these
loci but in its absence both IL-23 and IL-12 suppress IL-17
production while instead enhancing IFN𝛾 production in a
STAT4- and T-box transcription factor- (T-bet-) dependent
manner [34]. Furthermore, the Ifng locus was shown to
be semiactivated in Th17 cells and to rapidly acquire an
additional permissive state in response to IL-12 [35]. IL-
12 induces T-bet expression and repressive histone marks
in the Rorc locus [35]. T-bet then interacts with RUNX1
to disrupt RUNX1/ROR𝛾t interaction and activity [36]. In
the presence of IL-12, RUNX1 was also reported to bind to
the Ifng promoter [32]. T-bet and RUNX1/3 activation is
required for maximal IFN𝛾 production in “ex-Th17” cells. At
low RUNX1 levels, however, and in the presence of Th17-
promoting cytokines, the Th17 cell phenotype is retained.
Depending on the level of RUNX1 activation and which
cytokines are present, the formation of the RUNX1/T-bet
complex in Th17 cells leads to the development of IFN𝛾+IL-
17+ T cells independent of ROR𝛾t expression [32]. IFN𝛾+
Th17 cells have been shown to have the ATP-dependent
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Figure 1: Th17 cell plasticity. Cytokines IL-1𝛽, IL-6, and IL-23 activate the Th17 cell-specific differentiation program (centre) through
activating the transcription factor ROR𝛾t. IL-12 and IL-23 induce the transcription factors RUNX1/3 and T-bet inTh17 cells leading to IFN𝛾
and in some cases GM-CSF production. This is augmented by stimulation of the coreceptor ICOS (upper left). Exposure ofTh17 cells to IL-6
can induce IL-22 production (lower left). Treatment with biologic anti-TNF𝛼 agents or exposure to TGF𝛽 has been shown to promote IL-10
production accompanied by, in some studies, the expression of the transcription factor FoxP3. Th17 cells can also gain the ability to express
ectonucleotidase in response to TGF𝛽 (upper right). Finally, IL-4 can promote the generation of a Th17/Th2 cell type capable of producing
IL-4. These cells express the transcription factor GATA-3 (lower right).
membrane efflux pump P-glycoprotein/multidrug resistance
type 1 (MDR1) [17] (Figure 1).
Dendritic cell- (DC-) induced Th17 cell differentiation
in response to S. aureus has been shown to induce IL-10
production in addition to IL-17 [15, 37]. Similarly, treatment
of RA patients with biologic anti-TNF𝛼 agents induces IL-
10-producing Th17 cells [37]. The ability of Th17 cells to
produce IL-10 was shown to be regulated by one of the
transcription factors c-Maf and Aiolos [37, 38]. c-Maf, which
is also associated with aTh2 phenotype, represses expression
of Rora, Runx1, Il1r1, Ccr6, and Tnf genes [28]. Other studies
have shown that theTh17 cells can gain the ability to produce
IL-22 and IL-4 with IL-6 shown to induce the production of
IL-22 [39, 40]. Th17 cells can also express the transcription
factor associated with regulatory T cells [41] (Figure 1).These
observations are further evidence to indicate that Th17 cells
have the capacity for phenotypic and functional plasticity. In
this respect, studies of enriched memory Th17 cells showed
that the cells expressed 𝛽-catenin which is associated with
stem cell character and its T cell-specific binding partner
T cell factor 1 (Tcf1, also known as Tcf7) [18]. In contrast,
expression of Tcf1 is suppressed by T-bet in Th1 cells [18].
In addition, high levels of cyclins and reduced levels of
cyclin-dependent kinase (CDK) repressors were reported
in Th17 cells [14]. Reduction in CDK repressors has been
shown to be essential for self-renewal of haematopoietic
stem cells [42]. The chromosomal availability for binding
sites for Tcf1 was greatly increased in T cells engineered
with constituently active 𝛽-catenin. In these cells, Tcf1 was
found bound to the Rorc promoter activating the Th17 cell
differentiation [43]. These observations provide insights into
howTh17 cells can remain dormant until being stimulated by
appropriate antigens. Unlike other T cell subsets, the stem-
cell characteristics of Th17 cells apparently endow them with
the ability to retain the potential for renewal and functional
plasticity for long periods of time. Subsequent to TCR
engagement, the cytokine milieu regulates the phenotype of
“differentiated” Th17 cells. This ability can be used to harness
the therapeutic potential of these cells when considering
new vaccine strategies for inducing protective immunity to
extracellular pathogens and fungi and for treating patients
with cancer and autoimmune diseases.
3. Vaccination to Induce Pathogen-Specific
Th17 Responses
Th17 cells have a well-described role in immunity against
fungi and extra cellular bacteria, such asCandida albicans and
Streptococcus pneumoniae. Infection with these pathogens
is generally prevalent in immune compromised individuals,
especially in STAT3- andTh17-deficient patients [44]. It was,
therefore, proposed thatTh17 cell responses can be harnessed
by novel vaccine strategies to induce such cells to provide
protective immunity against these organisms. An interesting
issue as to whether the plasticity ofTh17 cells can be exploited
for the development of more effective vaccines has been
considered. For example, a number of studies have shown that
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the advantage of a vaccine that relies on inducing Th17 cell-
dependent responses would be that the protective immunity,
unlike the B cell-mediated immunity, will be independent
of pathogen serotype [45]. A further possible advantage of
Th17-inducing vaccines would be that infants and immune
compromised individuals that do not develop a good anti-
body response will benefit from long-lived memory Th17
cells [18, 45, 46]. To enhance Th17 responses by vaccination,
the use of various adjuvants has been assessed. The bacterial
components, muramyl dipeptide (MDP), lipopolysaccharide
(LPS), and CpG, augmentedTh17 responses [45, 47, 48].
Strategies to develop vaccines that specifically induce
Th17 cells in immune compromised individuals have also
been actively considered. These efforts were based on key
observations regarding the role of Th17 immunity at sites
most susceptible to infections in immune compromised
individuals. Thus, Th17-mediated immunity to C. albicans is
important for infections of the upper respiratory tract and
the skin [44, 49]. During such infections, fungal antigens
activate Dectin-1 and toll-like receptor 2 (TLR2) on dendritic
cells and this leads to the production of IL-23 and IL-1𝛽
[50]. Th17 cells generated in response to C. albicans, in turn,
induce the production of IFN𝛾 and, thus, further augment
cellular immunity [15]. A vaccine consisting of a recombinant
virulence factor used by Candida which has a similar shape
to a virulence factor in S. aureus (N-terminus of Als3p)
with aluminium hydroxide as adjuvant induced protective
immunity dominated by Th17 cells that produced both IL-17
and IFN𝛾 and recruited neutrophils [51].
In addition to fungal infections in which Th17 cell-
mediated immunity plays a critical protective role, these
cells are also important in immunity to the gram-positive
bacterium, Streptococcus pneumoniae. This bacterium causes
life-threatening infections of the respiratory tract in immune
compromised individuals and, in addition, leads to systemic
infection and septic arthritis [52]. There are over 90 different
serotypes of S. pneumonia and antibiotic resistance can
easily develop [53]. In children, natural protection against S.
pneumoniae is dependent on Th17 cells and this immunity
develops before antibody-mediated immunity [46]. During
the course of an infection, activated monocytes first recruit
Th17 cells which, in turn, recruit neutrophils to kill the
bacteria [54–56]. Furthermore, intranasal vaccination with
common cell wall polysaccharides, which bind MHCII,
has been shown to induce a Th17-dependent, antibody-
independent protective immunity [57, 58].
The gram-negative Pseudomonas aeruginosa is another
pathogen known to induce a Th17 response. This pathogen
can cause similar infections as C. albicans and S. pneumonia,
that is, sepsis and respiratory and gastrointestinal tract
infections, especially in immune compromised individuals
[59]. IL-17 production was noted in response to intranasal
vaccination with live attenuated P. aeruginosa, or a library
of P. aeruginosa proteins. The resulting immunity which was
mostly dependent on rapid neutrophil recruitment conferred
protection to several strains of the bacterium [59, 60].
The role of Th17-mediated protective immunity to the
respiratory tract is further highlighted by studies showing
immunity to conserved outer membrane proteins from sev-
eral serotypes of the gram-negative bacterium, Klebsiella
pneumonia [45]. Vaccination with this bacterium with LPS
used as adjuvant induced an MHCII-dependent Th17 cell-
mediated immunity [45].The resulting immune responsewas
serotype-independent and specific to conserved outer mem-
brane proteins. The response was also antibody-independent
and lasted for at least four weeks. In contrast, serotype-
specific immunity to polysaccharide capsular antigens from
K. pneumonia induced a transient B cell response [45].
Protection from Mycobacterium tuberculosis is also
known to involve Th17-mediated immunity. Thus, a study
noted that vaccination with M. tuberculosis induced pro-
tection associated with an IL-17-mediated response [11]. In
this study, IL-23 was shown to be essential for the acceler-
ated immune response to prevent bacterial growth and the
induction of Th17 cells in the lung. The recall Th17 response
occurred concurrently with the expression of chemokines
CXCL9, CXCL10, and CXCL11 that, in turn, recruited other
CD4+ cells that produced IFN𝛾 in the lung [11].
Another study reported that immunization with the
gram-negative Bordetella pertussis, which causes whooping
cough, induced immunity that was associatedwith the induc-
tion of Th17 cells. Thus, intraperitoneal immunization with a
whole B. pertussis vaccine twice, four weeks apart followed by
challenge with aerosol inoculation two weeks later, induced
a toll-like receptor 4- (TLR4-) dependent production of IL-
23 from DCs [61]. This augmented Th1 and Th17 responses
and led to protective cellular immunity that involved bacterial
killing by activated macrophages.
Although often associated with a Th1 immune response,
immunity to the respiratory syncytial virus (RSV) has also
been shown to induce aTh17 response in the respiratory tract.
A protectiveTh17-dependent response developed in a mouse
model concomitant with allergic asthma and also in infected
infants [62, 63]. Interestingly, a Pertussis vaccine induced
protection from RSV infections in neonatal mice when given
intranasally [64]. This vaccination led to modification of
the immune response by enhancing mucosal resistance to
RSV infection during adulthood. In this setting, IL-17 was
produced by Th17 and NK cells and led to the recruitment
of neutrophils. In addition, IL-17+IFN𝛾+ T cells were shown
to contribute significantly to the protection [64].
For certain bacteria, fungi, and at least one virus, vac-
cination that initiates Th17 responses can, therefore, confer
effective immune protection. Such vaccines often induce
immunity at mucosal surfaces that are dependent either
on a switch from IL-17-producing T cells to IL-17- and
IFN𝛾-producing cells, or a Th17-dependent recruitment of
IFN𝛾 producing Th1 cells (Figure 2(a)). In most situations
during recall responses, key cells that are eventually recruited
appear to be neutrophils, which facilitate the eradication
of pathogens [51, 55, 59, 64]. Issues to consider during
development of a vaccine inducingTh17 protective immunity
are the role of adjuvants and whether specific augmentation
of theTh17 cell phenotype can increase a favourable immune
response.
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Figure 2: The heterogeneity of Th17 cell phenotype and functions. (a) In immunity to pathogens, (b) in tumour pathology, and (c) in
promotion of autoimmune diseases. (a) Dendritic cells (DCs) are stimulated by pathogens to present antigens to induce the differentiation
of na¨ıve T-cells to Th17 cells. DCs produce IL-23 and IL-1𝛽 that facilitate the differentiation to and expansion of activated Th17 cells.
Pathogen-specific Th17 cells produce IL-17 and, in some cases, IFN𝛾. IL-17 production induces IL-8 production by endothelial cells leading
to neutrophil recruitment and pathogen eradication. Th17 cells can also recruit effector T cells for pathogen eradication. (b) Tumour
microenvironments influence the phenotype ofTh17 cells. TGF𝛽 inducesTh17 cells to produce vascular endothelia growth factor (VEGF) that
induces angiogenesis. However, whilst IL-17 can promote tumour development, IFN𝛾 produced byTh17 cells suppresses tumour development
through recruitment of other immune cells. (c) IL-17 can promote chronic inflammation and autoimmune diseases. For example, Th17 cells
infiltrate the blood brain barrier in patients with MS. In addition, IL-17 induces inflammation in dermal cells in patients with psoriasis.
Furthermore, IL-17 can induce angiogenesis and the production of other cytokines-, proteases-, and the receptor activator of nuclear factor
kappa-B ligand (RANK-L) from synoviocytes (SC) and osteoblasts (OB) in the synovium of RA patients activating osteoclasts (OC).
4. Harnessing Th17-Mediated
Protection from Cancer
Theability to augment the protective potential ofTh17 cells by
vaccination has actively been considered for treating cancer.
Several studies have identified Th17 cells in tumour masses
[65–67].However, the role ofTh17 cells in immunity to cancer
is somewhat controversial. As Th17 cells are characterised by
functional/phenotypic plasticity, they are likely, therefore, to
be differentially influenced by the complex nature of tumour
microenvironments (Figure 2(b)). Gastrointestinal tumour
development is, for example, driven by an inflammatory
environment due to chronic disease and disrupted barriers
or by the bacterial flora [68–70]. Th17 cells present in
these malignancies have been shown to promote tumour
development. One study observed that Th17 cells defined by
expression of the transcription factor BATF and IL-23 recep-
tor weremore prevalent in the lamina propria of patients with
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colitis-associated colon cancer than in healthy individuals
[69]. Studies in animal models revealed that Th17 cells were
induced to proliferate by IL-23 from adjacent antigen pre-
senting cells (APCs) [69]. Perhaps consistent with the stem
cell-like genotype of Th17 cells, 𝛽-catenin produced by Th17
cells in the colon gradually increases comparing patients with
ulcerative colitis and colon cancer [43]. In an animal model,
colitis-induced cancer was strongly linked to stabilization of
𝛽-catenin in T cells. 𝛽-catenin’s binding partner Tcf1 was
shown bound to the promoter of ROR𝛾t, thus, leading to
increased Th17 cell proliferation and cancer development
[43]. The proposition that microorganisms influence the
inflammatory tumour microenvironment through stimulat-
ing Th17 cells is supported by the outcome of three studies.
One study revealed that, early during the development of
colorectal cancer, impaired mucus production leads to the
loss of barrier functions [68].This resulted inmicrobial prod-
ucts accessing tumour sites and leading to the production of
IL-23 by myeloid cells which, in turn, increased size of the
tumour through inducing Th17 cells [68]. The second study
observed that the bacterium enterotoxigenic Bacteroides
fragilis in the colon caused inflammation and proliferation of
colonic epithelia leading to the recruitment ofTh17 cells. The
resulting combination of hyperproliferation of the epithelia,
Th17 recruitment, and expansion led to chronic inflammation
and colon carcinogenesis [70]. The third study observed
that released enteropathogenic bacteria-secreted particles
stimulated the intestinal epithelium to produce exosome-like
nanoparticles that promoted colon cancer.The nanoparticles,
intestinal mucosa-derived exosome-like nanoparticles, con-
tained sphingosine-1-phosphate, CCL20, and PGE
2
. CCL20
recruited T cells from circulation while PGE
2
facilitatedTh17
cell differentiation leading to the development of colon cancer
[27]. Although IL-17 can mediate tumours through causing
or enhancing chronic inflammation, the cytokine can also
act directly on tumour cells. One study reported that the
IL-17 receptor A (IL-17RA) was expressed on transformed
epithelial cells and these developed into colorectal tumours.
These epithelial cells where the main site for protumorigenic
activity by IL-17 (Figure 2(b)) [71]. Also the inflammatory
environment at other sites than the gastrointestinal tract can
induce tumour promoting Th17 cells. Two studies showed
that the inflammatory environments in the skin induced by
tumour cells or by tumour-derived fibroblasts led to such
Th17 recruitment and IL-17-dependent tumour development
[72, 73].
Some studies have revealed that Th17 cells can promote
cancer if they are the only immune cells found in the
tumour but have protective functions in the presence of
other immune cells [74]. CD39 and CD73 ectonucleotidase-
expressing Th17 cells, induced by IL-6 and TGF-𝛽, were
reported to be immunosuppressive in several mouse tumours
[75]. The ectonucleotidases-degraded ATP led to adenosine
release and, subsequently, suppression of helper CD4+ and
cytotoxic CD8+ T cell effector functions. TGF𝛽 which is
commonly found in tumour microenvironments has, there-
fore, been suggested to augment the immune suppressive
and tumour-promoting functions of Th17 cells [75, 76].
Th17 cells have also been reported to promote cancer by
virtue of their ability to induce angiogenesis [65]. Zhang
and colleagues noted that increased numbers of intratumoral
IL-17-producing cells correlated with microvessel density in
the tumours and with poor survival of patients with hepa-
tocellular carcinoma [67]. Another study reported that high
IL-17 levels in patients with colorectal carcinoma correlated
with bad prognosis. In these tumours, Th17 cells facilitate
angiogenesis through their ability to induce the production of
vascular endothelial growth factor (VEGF) from cancer cells
[77]. Indeed, Wang and colleagues reported on the depen-
dence of angiogenesis and experimental melanoma tumour
growth on IL-17 [78]. Interestingly, however, angiogenesis
promoted by IL-17 was reduced considerably when IFN𝛾+
cells were present in the tumour. This observation could be
taken as support for the notion that the presence of other
immune cells within tumours promotes a protective role by
Th17 cells [78]. The notion that coexpression of IFN𝛾 and
IL-17 is favourable for tumour immunity was supported by
another study of ovarian cancers [66]. In this study, the
importance ofTh17 cells was suggested by the low number of
tumour-infiltratingTh17 cells and the low level of IL-17 in the
ascites in patients with more advanced disease. Through the
synergistic action between IL-17 and IFN𝛾,Th17 cells induced
the production of CXCL9 and CXCL10 to recruit effector T
cells [66].Muranski and colleagues also showed that adoptive
transfer of Th17 cells led to the killing of established tumours
more efficiently than the transfer of other effector T cell
subsets [18].The authors noted that IL-17+IFN𝛾+ T cells were
more efficient in cancer eradication than IFN𝛾+ T cells. This
was believed to be because the cells were not terminally
differentiated and less prone to apoptosis than terminally dif-
ferentiated IFN𝛾+Th1 cells [18].The potential involvement of
IFN𝛾+Th17 cells in providing protective immunity to cancer
was highlighted in two further studies. In an animal model
involving transplanted solid tumour, bacterial DNA (CpG-)
stimulated plasmacytoid DCs (pDCs) presented tumour
antigens to Th17 cells. The ability to shrink tumours was
dependent on this antigen presentation to Th17 cells and the
cells also gaining the ability to produce IFN𝛾 [48]. Immune
cells including cytotoxic CD8+ T cells were subsequently
recruited by Th17 cells, mediating protective antitumour
immunity [48].The inducible costimulatory receptor (ICOS)
is expressed on Th17 cells and other immune cells. Interest-
ingly, stimulation of ICOS onTh17 cells in vitro induced IFN𝛾
production (Figure 1). In contrast, anti-CD28 costimulation
favoured an IL-17 phenotype only [79] Furthermore, IFN𝛾+
Th17 cells developed through costimulationwith ICOS ligand
were superior to cells costimulated with anti-CD28 in regres-
sion of human tumour engrafted into mice [79].
In conclusion, it is evident that Th17 cells can have
paradoxical roles in cancer (Figure 2). It is not currently
established if it would be possible to pharmacologically
modulateTh17 cells for suppressing cancer. Inhibition ofTh17
cells by anti-IL17 therapy or through inhibition of ROR𝛾t
could be favourable in situations whereTh17 have angiogenic
activity [80–83]. Although anti-IL17 therapy has been shown
to worsen Crohn’s disease, a study using an animal model
of colonic tumour revealed that the therapy can be effica-
cious as a neoadjuvant in combination with chemotherapy
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[71]. In settings where the tumour microenvironment alters
Th17 function to one that augments tumour development,
therapeutic strategies could be considered to harness the
cells to a protective phenotype such as inducing the cells to
coproduce IFN𝛾. This suggestion is based on observations
cited above that protective immunity to tumours by Th17-
like cells is more likely to be achieved if the tumour contains
T cells that produce IFN𝛾 [74]. Specific stimulation of the
coreceptor ICOS was reported to be capable of skewing
Th17 cells to become IFN𝛾/IL-17-producing cells which have
been revealed to be beneficial for tumour suppression [18,
79]. Furthermore, vaccination with tumour antigens using
peptidoglycan or CpG as adjuvants for the activation of DCs
or pDCs, respectively, has also been shown to augment a
favourableTh17 response [47, 48]. Based on the observations,
novel pharmacological agents and adjuvants that can alter the
phenotype of Th17 cells should be tested in animal models of
cancer. ICOS engagement has, however, also been associated
with promotion of autoimmune diseases as its stimulation
increases the number of effector Th17 cells [84]. Each agent
developed for the purpose of inducing cancer-suppressing
Th17 cells should, therefore, be tested both for antitumour
properties and the ability to promote autoimmunity.
5. Therapeutic Considerations Involving Th17
Cells in Autoimmune Diseases
In addition to their critical role in providing effective immu-
nity to pathogens, especially on mucocutaneous membranes
and possible involvement in tumour eradication, Th17 cells
have been implicated in autoimmune diseases [19–23, 85]. For
example, there is good evidence for multiple roles for Th17
cells and for IL-17 in plaque growth in patients with psoriasis,
synovial inflammation, increased angiogenesis and bone
degradation in patient with RA and ankylosing spondylitis.
The cells have also been suggested to have a role in disruption
of the blood brain barrier in multiple sclerosis (Figure 2(c))
[19, 20, 85]. The beneficial therapeutic effect of the anti-
IL-17 antibody ixekizumab and the anti-IL-17 receptor anti-
body brodalumab in psoriasis, psoriatic arthritis, ankylosing
spondylitis, and refractory RA is further evidence for the
involvement of Th17 cells in these disorders [19–23]. Novel
strategies are under development for selective targeting of
Th17 cells through inhibiting the nuclear receptor ROR𝛾t
[80–83].
As cited above, the available evidence suggests that IFN𝛾-
producing Th17 cells are beneficial when considering the
development of vaccines for infectious diseases and in some
cancers [18, 48, 51, 79]. However, several studies have impli-
cated IFN𝛾+ Th17 cells in the pathogenicity of autoimmune
diseases. For example, experimental colitis in mice is driven
by IL-23-induced IFN𝛾+IL17+ T cells that express the IL-
23 receptor [86]. Importantly, the same cells were found in
the lamina propria of the intestine in patients with Crohn’s
disease [86, 87]. In juvenile arthritis, Th17 cells change to
a Th1 phenotype while migrating from the circulation to
inflamed joints. This conversion can be facilitated in vitro by
incubating Th17 cells with TGF𝛽 and high IL-12 levels [88].
Highly enriched Th17 cells from diabetic BDC2.5 transgenic
mice adoptively transferred diabetes to NOD/SCID recipi-
ents, conferred pathology when the cells were modified to
a Th1 phenotype [89]. Furthermore, circulating Th17 cells
from relapsing MS patients show an increased propensity
to change to IFN𝛾-producing Th17 cells. These cells were
also found in brain tissues of patients with multiple scle-
rosis (MS) [90]. In the animal model of MS, experimental
allergic encephalomyelitis (EAE), IFN𝛾-producingTh17 cells
preferentially crossed the blood brain barrier to accumulate
in the central nervous system. The IL-17+IFN𝛾+ T cells
displayed better migratory potential than IFN𝛾-producing
Th1 cells or non-IFN𝛾-producingTh17 cells [90]. However, a
number of other studies disagree with the notion that IFN𝛾-
producingTh17 cells are pathogenic in autoimmune diseases.
For example, in mice with EAE neither IL-17 nor IFN𝛾
deficiency inhibited disease development and symptoms [91,
92]. Instead, it was noted that Th17 cells conferred pathology
when the cells gained the ability to produceGM-CSF [93, 94].
Furthermore, two recent studies revealed that, in EAE and in
patients with MS, GM-CSF is produced by a separate T cell
subset than byTh17 cells [95, 96]. In addition, overexpression
of T-bet in T cells during collagen induced arthritis (CIA)was
found to reduce bone erosion [97]. Studies in our laboratories
have shown that patients with RA who do not respond to
treatmentwith biologic anti-TNF𝛼 agents produce high levels
of IL-17 [98]. Although IL-17 induces bone resorption in
patients with RA, IFN𝛾, perhaps paradoxically, is associated
with less bone erosion indicating that the development of IL-
17+IFN𝛾+ phenotype could associate with a better outcome
at least for bone loss in the disease [99]. Taken together, these
observations suggest that althoughTh17 cells have pathogenic
roles in autoimmune diseases there is also evidence to suggest
that not all Th17 cell subsets confer pathology. Furthermore,
as cited above, the presence of IFN𝛾-producing Th17 cells
could have beneficial protective roles in infections and cancer
[18, 51].There is also evidence that someTh17 cells in patients
with RA treated with biologic anti-TNF𝛼 agents gained a
functionally distinct phenotype and produced IL-10 [37].
Clearly, therefore, there is more to discover regarding how
Th17 cells and how their plasticity contribute to protective
immunity and to inflammatory diseases.
Although augmenting Th17-mediated immunity by vac-
cination holds promise for infectious diseases and, possibly,
for cancer, one caveat is that the approach will not be without
risks of promoting autoimmune inflammatory diseases. It
is, therefore, of great importance to determine whether
different antigens have different propensities to induce Th17-
mediated autoimmunity and whether some individuals are
more predisposed genetically to such responses [45, 100].
ICOS engagement might be one such example as activation
of pathway associated with the coreceptor has been shown
to induce Th17 cells capable of ameliorating cancer but also
Th1 and Th17 cells with ability to induce arthritis [79, 84].
Whether or not induced Th17 cells could mediate or trigger
autoimmune diseases in susceptible individuals should be
evaluated in experimental models of diseases such in CIA
and in EAE. So far, however, no study has reported on the
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development of autoimmune symptoms through inducing
Th17-mediated responses to infectious pathogens. In humans,
a polymorphism in the DECTIN1 gene, leading to reduced
ability to stimulate IL-17 production, was not associated with
susceptibility to or severity of RA [101]. It is also possible
that theTh17 subset(s) that is protective in infectious diseases
could be distinct from Th17 cells that promote autoimmune
disease pathology as has been suggested [25]. Indeed, there is
some evidence to show that patients with RA have Th17 cells
that are unable to eradicate C. albicans suggesting that the
role of these cells in pathology may not directly be associated
with their ability to produce IL-17 [102]. In this respect, IL-
17 is known to confer protection of inflamed gastrointestinal
tracts from fungal infections suggesting that future treatment
options could benefit from avoiding simple blockade of the
cytokine [24]. If manipulation of Th17 is safe, it would be of
interest to knowwhether augmenting the transcription factor
RUNX1 for IL-17+IFN𝛾+ T cell phenotype induction will be
beneficial in treating patients with cancer and autoimmune
diseases.
6. Concluding Remarks
There is a steady increase in knowledge about Th17 cells
and their role in different clinical settings since they were
first discovered in 2006. As these cells are involved both in
immunity against pathogens and in promoting autoimmune
diseases and perhaps some cancers, the development of
therapeutic strategies to harness Th17-mediated responses
is already an area of huge interest. Augmentation of Th17
cell-dependent but antibody-independent vaccination for
certain pathogens is under active development. Such an
approach would have the benefit of triggering protective
immunity that is serotype-independent and suitable for
children, immune compromised individuals, and individuals
with impaired B cell-mediated immunity. However, the fact
that at least some Th17 subsets could play pathogenic roles
in some autoimmune diseases and, possibly, in some cancers,
targeted inhibition or modulation of the function of these
cells could also be immensely beneficial. Strategies that
rely on developing novel specific molecules to modulate
Th17 cells are already underway. Perhaps what complicates
the development of such strategies is the plasticity of the
phenotype and functions of Th17 cells which are, clearly,
noted to be more than other T cell subsets. This plasticity is
likely to hamper the development of strategies to modulate
Th17 cells in cancer as the tumour microenvironment and
presence of other immune cells could influence the outcome
of such treatments. Specific augmentation, for example, by
inducing IFN𝛾 production by Th17 cells, has been shown to
be beneficial inmany infectious diseases and in some cancers.
Although IFN𝛾-producing Th17 cells have been suggested
to be associated with autoimmune diseases in some studies,
there is currently limited evidence that such cells can actually
lead to autoimmune disease development. Future treatment
options for vaccination for infectious diseases, cancers, and
autoimmune diseases might involve augmentation of distinct
Th17 cell subsets for beneficial outcomes. Th17 cells are
arguably the T cell subset that has coevolved with us for
the longest time. Increased knowledge of these cells in health
and in disease could be of immense future benefit.
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